|
Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101). |
|
|
Honoraria - NCCN; UpToDate |
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech |
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst) |
Travel, Accommodations, Expenses - advisory boards/consultancy |
|
|
Consulting or Advisory Role - Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer |
Research Funding - Merck (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Roche |
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst) |
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Sanofi |
|
|
Honoraria - Astellas Pharma; Novartis; Pfizer |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai |
Research Funding - Exelixis; Janssen; Novartis; Pfizer |
|
|
Honoraria - Bayer; Janssen Oncology; Pfizer; Sanofi |
Consulting or Advisory Role - Bayer; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Bayer; Janssen Oncology; Pfizer; Sanofi |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst) |
|
|
Honoraria - Astellas Pharma; Novartis; Ono Pharmaceutical; Pfizer; Sanofi |
Consulting or Advisory Role - Novartis; Ono Pharmaceutical |
Research Funding - Astellas Pharma; AstraZeneca; Pfizer |
|
|
Honoraria - Novartis; Ono Pharmaceutical; Pfizer |
Consulting or Advisory Role - Bayer; Janssen; Novartis; Ono Pharmaceutical |
Speakers' Bureau - Bayer; Novartis; Sanofi |
Research Funding - Astellas Pharma; AstraZeneca; Janssen; Novartis; Ono Pharmaceutical; Pfizer; Takeda |
|
|
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Ipsen (Inst); Novartis; Pfizer; Sanofi |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Alkermes; Amgen; Bristol-Myers Squibb; C-Cam; Genentech; Genoptix; GlaxoSmithKline; Infinity Pharmaceuticals; Lilly; Merck; Nektar; Novartis; Pfizer; X4 Pharma |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Eisai; Exelixis; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |